Allez Health, previously known as Zense-Life, has successfully raised $60 million in a Series A financing round, with Korean in-vitro diagnostics company, Osang Healthcare, leading the funding as a strategic investor. The San Diego-based company, founded by experts in the continuous glucose monitoring (CGM) industry, plans to utilize this new capital to accelerate growth towards pivotal trials, support regulatory approval filings, and scale manufacturing operations.
The leadership team at Allez Health includes Chief Technology Officer Robert Boock and Chief Science Officer Ted Zhang. Boock, known as the lead inventor of the Dexcom G4 CGM, and Zhang, who led the development of G4’s sensor membrane, bring a wealth of experience to the company. Advisor Frank Westerman, who co-founded mySugr acquired by Roche in 2017 and Leif Bowman who co-founded the company and serves as CEO complete the team.
Allez Health is focused on developing a CGM biosensor platform with innovative sensor technology that aims to disrupt the current cost barrier associated with CGM devices while improving performance and user experience. Their platform offers a 15-day wear time with real-time data and eco-friendly components. The company currently holds seven issued patents and has more than 40 pending patent applications. Allez Health has been part of over 80 clinical studies involving more than 1,500 users including a pivotal study with 120 users.
With the completion of its pivotal study and successful funding secured
